Rocket can resume gene therapy trial after FDA lifts hold
The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died earlier this year.
Previous Post
Should Chest CT be Routine for Prostate Cancer Patients on Androgen Deprivation Therapy?
Next Post
Third-generation CRISPR: brushing off the genetic cobwebs
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago